<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315497</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5502</org_study_id>
    <secondary_id>U54AR057319</secondary_id>
    <nct_id>NCT00315497</nct_id>
  </id_info>
  <brief_title>Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis</brief_title>
  <official_title>Longitudinal Protocol for Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only
      occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis. In order to
      properly treat this disease, it is critical that the level of disease activity can be
      determined over the course of the disease. The purpose of this study is to determine new
      biological markers, or biomarkers, that may be used to assess the severity of disease in
      people with GCA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GCA is a rare autoimmune disorder and is the most common type of inflammation of medium- to
      large-sized blood vessels in the body. It usually only occurs in older adults. The most
      common symptoms of GCA include headache, pain in the shoulders and hips (polymyalgia
      rheumatica), pain in the jaw (jaw claudication), fever, and blurred vision. Organ-specific
      markers of injury or damage as well as direct markers of vascular damage and inflammation are
      currently used by clinicians to assess GCA disease progression; however, these markers are
      not very useful in guiding treatment. There are also blood tests that clinicians use to
      monitor GCA activity, such as erythrocyte sedimentation rate (ESR) and C-reactive protein
      (CRP), but these tests lack specificity and sensitivity. Most treatments available now for
      GCA are toxic, therefore if other markers indicating disease activity can be found, it may
      lead to the development of less toxic treatments. This study will use new scientific methods
      to identify new biomarkers that can be used to monitor disease activity in GCA patients.
      These biomarkers may be used to help direct clinical care for GCA patients and assist in
      future drug development.

      Study visits will occur monthly for the first year, then every 3 months thereafter for the
      remainder of the study. Blood and urine collection will occur at every visit. A physical exam
      and medical and medication history will occur every 3 months; also, participants will be
      asked to complete several questionnaires to assess disease activity, health status, and
      tobacco, alcohol, and drug use. Participants may have additional study visits if a disease
      flare or disease-related complications occur during the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discover biomarkers in Giant cell arteritis capable of measuring disease activity and response to treatment.</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the predictive value of biomarkers for clinical outcome in Giant cell arteritis.</measure>
    <time_frame>Study completion.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Temporal Arteritis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma), urine, and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with giant cell arteritis. Enrollment will be sequential and participants will have
        disease in various stages and of different duration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of GCA, meeting at least 3 of the following 5 American College of
             Rheumatology (ACR) criteria for the diagnosis of GCA:

               1. At least 50 years of age at disease onset

               2. New onset or new type of localized pain in the head

               3. Temporal artery abnormality (i.e., temporal artery tenderness to palpation or
                  decreased pulsation unrelated to arteriosclerosis of cervical arteries)

               4. ESR of greater than 40 mm in the first hour by the Westergren method

               5. Temporal artery biopsy showing vasculitis characterized by a predominance of
                  mononuclear cell infiltration or granulomatous inflammation, usually with
                  multinucleated giant cells

        Exclusion Criteria:

          -  Unable to give informed consent and sign the consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A. Merkel, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Amudala, NP</last_name>
      <phone>617-414-2512</phone>
      <email>namudala@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul A. Monach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Jaquith</last_name>
      <phone>507-284-4502</phone>
      <email>jaquith@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven R. Ytterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kisela</last_name>
      <email>kiselae@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol A. Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Minal Hatwar</last_name>
      <email>Bhagyavati.Hatwar@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope</last_name>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader A. Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Vendramini</last_name>
      <email>judy.vendramini@sinaihealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Carette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/vcrc</url>
    <description>Vasculitis Clinical Research Network</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu</url>
    <description>Rare Disease Clinical Research Network</description>
  </link>
  <reference>
    <citation>González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003 Aug;33(1):38-48. Review.</citation>
    <PMID>12920695</PMID>
  </reference>
  <reference>
    <citation>Goronzy JJ, Weyand CM. Cytokines in giant-cell arteritis. Cleve Clin J Med. 2002;69 Suppl 2:SII91-4. Review.</citation>
    <PMID>12086274</PMID>
  </reference>
  <reference>
    <citation>Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000 May;43(5):1041-8.</citation>
    <PMID>10817557</PMID>
  </reference>
  <reference>
    <citation>Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003 Sep 16;139(6):505-15. Review.</citation>
    <PMID>13679329</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Giant Cell Arteritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

